Published in:
22-10-2022 | Spironolactone | Ischemic Heart Disease (D Mukherjee, Section Editor)
The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management
Published in: Current Cardiology Reports | Issue 12/2022
Login to get accessAbstract
Purpose of Review
Finerenone is a novel, non-steroidal mineralocorticoid receptor antagonist (MRAs) that has been investigated for the management of cardiorenal conditions. This article provides an overview of recent evidence of benefits on cardiovascular (CV) outcomes.
Recent Findings
The recently published phase III FIDELIO-DKD and FIGARO-DKD, alone and pooled, in patients with CKD and diabetes demonstrate that finerenone reduces the composite of CV death, non-fatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure (HF) with hospitalization for HF being the primary driver of this composite.
Summary
Finerenone is indicated to reduce renal and CV outcomes in patients with CKD and diabetes. Future investigations of this agent include patients with non-diabetic CKD, HF with preserved ejection fraction, and with the use of sodium-glucose transporter type 2 inhibitors.